This week, the FDA granted Priority Review designation to 4 therapies. The designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.
This week in oncology news, the FDA granted Priority Review designation to 4 therapies. The Priority Review designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.
In addition, the American Cancer Society released an update on the cancer mortality rate, and new data were reported from the 2021 Gastrointestinal Cancer Symposium.
The FDA has accepted a Biologics License Application for narsoplimab and granted it Priority Review for use as treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
The FDA has granted a Priority Review to the combination of nivolumab with fluoropyrimidine- and platinum-containing chemotherapy, which is a potential treatment option for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
The FDA accepted a supplemental Biologics License Application for nivolumab as adjuvant treatment of patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiation therapy and granted it Priority Review.
Cancer mortality has been on a continuous decline since its peak in 1991, resulting in an overall reduction of 31% in the mortality rate and approximately 3.2 million fewer cancer deaths in the United States.
In an interview with Targeted Oncology, Yelena Y. Janjigian, MD, provided important highlights from the DESTINY-Gastric01 trial and explained the overall impact of the FDA approval of trastuzumab deruxtecan for oncologists treating patients with HER2-positive advanced gastric cancer or GEJ cancers.
Pembrolizumab monotherapy demonstrated durable antitumor activity and encouraging effects on survival in an evaluation of patients with previously untreated hepatocellular carcinoma.
Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.
Subsequent observations related to the COVID-19 have led to the discovery cardiac manifestations, gastrointestinal complications, and hematological manifestations associated with this virus.